Background and Introduction: Sesquiterpene lactones are a class of secondary metabolite
that consist of sesquiterpenoids and lactone ring as pharmacophore moiety. Large group of
bio-active secondary metabolites as phytopharmaceuticals belong to this category. Asteraceae
family based medicinal plants, from which more than 5,000 sesquiterpene lactones have been
reported so far. Sesquiterpene lactone-based pharmacophore moieties hold promise for broadspectrum biological activities against cancer, inflammation, parasitic, bacterial, fungal, viral
infection and other functional disorders. Moreover, this moiety based phytocompounds have
been spotlighted with new dimension in the natural drug discovery program worldwide after
2015 Medicine Nobel Prize achieved by the Artemisinin researchers.
Objective: These bitter substances often contain an α, β-unsaturated-γ-lactone as a major
structural backbone, which in recent studies has been explored to be associated with antitumor, cytotoxic, anti-inflammatory action. Recently, outlook of sesquiterpene lactones as
phytomedicine has been increased. This study will be reviewed the future prospect of
sesquiterpene lactones against inflammation and cancer.
Methods: Hence, we have emphasized the different features of this moiety by incorporating
its structural diversity on biological activities to explore structure activity relationships (SAR)
against inflammation and cancer.
Results: How dual mode of action as anti-inflammatory and anti-cancer have been
envisioned by this phytopharmaceuticals will be forecasted in this study. Furthermore, the corelation of anti-inflammatory and anti-cancer activity executed by the sesquiterpene lactones
for fruitful phytotherapy will be revealed in the present review in the milieu of
pharmacophore activity relation and pharmacodynamics study as well.
Conclusion: So, these metabolites are paramount in phytopharmacological aspects. The
present discussion on future prospect of this moiety based on the reported literature could be
the useful guide for anti-inflammatory and anti-cancer drug discovery program for the